小児急性非リンパ性白血病(ANLL)に対するModified VAPA療法の治療成績

諸橋 文雄; 青沼 架佐賜; 加藤 正雄; 小林 敏美; 花岡 康彦; 辻 浩一郎; 野呂瀬 昇; 川合 博; 中畑 龍俊; 塚田 昌滋; 小宮山 淳; 赤羽 太郎

doi:10.11406/rinketsu.27.2101

Modified VAPA Therapy for Children with Acute Nonlymphocytic Leukemia

Fumio MOROHASHI, Kesashi AONUMA, Masao KATOH, Toshimi KOBAYASHI, Yasuhiko HANAOKA, Kohichiro TSUJI, Noboru NOROSE, Hiroshi KAWAI, Tatsutoshi NAKAHATA, Masashige TSUKADA, Atsushi KOMIYAMA, Taro AKABANE

Author information

Keywords: acute nonlymphocytic leukemia, modified VAPA therapy, central nervous system prophylaxis, supportive care

JOURNAL RESTRICTED ACCESS

1986 Volume 27 Issue 11 Pages 2101-2106

DOI https://doi.org/10.11406/rinketsu.27.2101

Details

Abstract

Thirteen children with acute nonlymphocytic leukemia (ANLL) in first remission were treated with modified VAPA therapy including central nervous system (CNS) prophylaxis.
Twelve of 13 patients remain in continuous complete remission and 6 patients are in off therapy. A Kaplan-Meier analysis of patients predicts that 90.9% of patients will remain in remission at 2yr. Only one patient with FAB subtype M2 and high WBC count (182,500/cmm) had a bone marrow relapse.
Toxicities of this therapy consist of vomiting, marrow suppression and cardiotoxicity. However, with the intensive supportive care, patients were well tolerated.
We have concluded that modified VAPA therapy is very successful therapy for children with ANLL.

Corresponding author

Register with J-STAGE for free!